Objective  To explore the production and quality standard of an inactivated plasma of anti-2019 novel coronavirus(2019-nCoV) prepared from convalescent plasma of COVID-19 patients. Methods  Four hundred and forty-one convalescent samples were collected from COVID-19 patients in Wuhan, China from January to March 2020 and screend for pathogens including 2019-nCoV, HIV, Treponema pallidum and so on. Qualified plasma samples were inactivated by methylene blue light. By carrying out protein content of plasma , anti-2019-nCoV antibody, coagulation factor Ⅷ activity and other tests, the effect of methylene blue light inactivation on plasma was determined and the quality standard was dstablished. Results  Protein content of inactivated plasma did not change significantly before and after methylene blue irradiation inactivation ,coagulation factor Ⅷ activity was ≥ ≥0.50 I U/ml.Antibody titer did not show a significant decrease.All test results met the queality requeirement. Conclusion  The key quality control and process parameters of anti-2019-nCoV inactivated plasma prepared from the plasma of COVID-19 convalescent patients are established.